Cell Therapy News/Articles, page-16889

..... and ? How embarrassing for you ? That quote is from the 2022 Annual Report (page 2) but you already knew that when you replied to the post from Pledge ..... as @reginaldp would say - keep punchin'


69849157





You know very well we are talking about the FDA CHF meeting that is continually referred to in 2023 ASX announcements (after 2022 Annual Report was issued) and this FDA CHF meeting was planned after the FDA requested additional information from the DREAM-HF phase 3 trial late last year and that it hasn't happened yet no matter what you have claimed (incorrectly) today .... nice try though






Mesoblast plans to meet with the US Food & Drug Administration (FDA) next quarter under its existing regenerative medicine advanced therapy (RMAT) designation to discuss common mechanisms- of-action across the spectrum of chronic HFrEF patients from NYHA class II/III to those with an implanted LVAD, and potential pathway to marketing approval.